Bristol Myers Squibb Pharmaceutical Company

Bristol Myers, schizophrenia

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.

Business Insider · 3d

Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older

Bloomberg on MSN · 3d

Bristol Myers Says New Schizophrenia Drug Off to Strong Start

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.

Hosted on MSN · 3h

Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts

Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1%.

17don MSN

Is Bristol-Myers Squibb Company (BMY) Among the Best Pharma Dividend Stocks to Buy In 2024?

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Yahoo Finance11d

Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks. As retirement approaches, ensuring financial stability becomes ...

pharmaphorum4d

A history of Bristol-Myers Squibb

Squibb founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers invested $5000 into a struggling drug manufacturing firm in ...

Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...

Seeking Alpha3d

BMY Bristol-Myers Squibb Company

View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.

Pharmaceutical Technology18d

Relatlimab by Bristol-Myers Squibb for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

Some results have been hidden because they may be inaccessible to you

Show inaccessible results